Ocular onchocerciasis

Summary

Ocular onchocerciasis (MONDO:0005878) is a disease. A subtype of onchocerciasis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	ocular onchocerciasis
Mondo ID	MONDO:0005878
EFO	EFO:0007398
MeSH	D015827
NCIT	C34862
SNOMED CT	240842000
UMLS	C0029002
MedGen	45196
GARD	0024250
Anatomy (UBERON)	UBERON:0010230
Is cancer (heuristic)	no

Also known as: eyeball of camera-type eye onchocerciasis · onchocerciasis of eyeball of camera-type eye

Disease family

This is a subtype of onchocerciasis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › parasitic infectious disease › helminthiasis › Nematoda infectious disease › Rhabditida infectious disease › onchocerciasis › ocular onchocerciasis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

No approved or late-stage (phase ≥3) drug is indicated for this disease; the following are in earlier-phase trials only.

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Albendazole, Ivermectin.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.